Belluscura (BELL) Competitors

Belluscura (LON:BELL) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Is BELL or NCYT more profitable?

Belluscura has a net margin of 0.00% compared to Novacyt's net margin of -244.34%. Novacyt's return on equity of -27.46% beat Belluscura's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belluscura	N/A	-97.35%	-48.17%
Novacyt	-244.34%	-27.46%	-13.43%

Does the MarketBeat Community favor BELL or NCYT?

Novacyt received 36 more outperform votes than Belluscura when rated by MarketBeat users.

Company	Underperform	Outperform
Belluscura	N/A	N/A
Novacyt	Outperform Votes 36 58.06%	Underperform Votes 26 41.94%

Do analysts rate BELL or NCYT?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belluscura	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Novacyt	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Do insiders and institutionals have more ownership in BELL or NCYT?

6.3% of Belluscura shares are held by institutional investors. Comparatively, 0.1% of Novacyt shares are held by institutional investors. 56.3% of Belluscura shares are held by insiders. Comparatively, 3.2% of Novacyt shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility & risk, BELL or NCYT?

Belluscura has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Novacyt has a beta of -1.86, suggesting that its share price is 286% less volatile than the S&P 500.

Which has stronger valuation & earnings, BELL or NCYT?

Belluscura has higher earnings, but lower revenue than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Belluscura, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belluscura	£1.20M	16.84	-£18.52M	-£0.11	-109.09
Novacyt	£11.58M	3.56	-£27.80M	-£0.39	-149.73

Does the media favor BELL or NCYT?

In the previous week, Novacyt had 1 more articles in the media than Belluscura. MarketBeat recorded 1 mentions for Novacyt and 0 mentions for Belluscura. Novacyt's average media sentiment score of 0.75 beat Belluscura's score of 0.00 indicating that Novacyt is being referred to more favorably in the news media.

Company	Overall Sentiment
Belluscura	Neutral
Novacyt	Positive

Summary

Belluscura beats Novacyt on 8 of the 14 factors compared between the two stocks.